– Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment – Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year – Current cash of approximately $100 million now extends cash …









